Literature DB >> 2163967

Interaction between hepatitis B surface proteins and monomeric human serum albumin.

B Krone1, A Lenz, K H Heermann, M Seifer, X Y Lu, W H Gerlich.   

Abstract

HBsAg is known to bind to human serum albumin polymerized by glutaraldehyde, human serum albumin has been found in preparations of HBsAg by several investigators. However, it is not yet known whether natural human serum albumin binds to hepatitis B virus under physiological conditions. We studied the binding between natural or recombinant HBsAg and monomeric human serum albumin by immunological, biochemical and biophysical methods. The binding capacity of 20-nm HBs spheres was variable but ranged up to six molecules HSA/sphere. A reversible binding site for human serum albumin was exclusively localized in the preS2 domain, whereas the S domain was inactive in vitro. Human serum albumin copurified with HBsAg of human origin during gel chromatography or sucrose-gradient centrifugation. This human serum albumin was monomeric in sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The preS2-bound part of the human serum albumin could be removed from HBsAg by high-salt, such as CsCl centrifugation, but another part could only be removed by treatment with a disulfide cleaving reagent. Most of this covalently bound human serum albumin was retained at the HBsAg particle after complete cleavage of medium-sized HBs protein with trypsin. This indicates a second way in which albumin binds irreversible to cysteine(s) of the small HBs protein (SHBs, P24 and GP27).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2163967     DOI: 10.1002/hep.1840110622

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  14 in total

1.  Study on hepatitis B virus pre-S/S gene mutations of renal tissues in children with hepatitis B virus-associated membranous nephropathy.

Authors:  Se Eun Kim; Yeong Hong Park; Woo Yeong Chung
Journal:  Pediatr Nephrol       Date:  2006-06-22       Impact factor: 3.714

Review 2.  Viral and cellular determinants involved in hepadnaviral entry.

Authors:  Dieter Glebe; Stephan Urban
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 3.  Hepatology.

Authors:  P M Harrison; J Y Lau; R Williams
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

Review 4.  Viral hepatitis.

Authors:  J Y Lau; G J Alexander; A Alberti
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

5.  Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins.

Authors:  R Thomssen; S Bonk; A Thiele
Journal:  Med Microbiol Immunol       Date:  1993-12       Impact factor: 3.402

6.  Use of a medium devoid of any human or animal compound (SMART2) for embryo culture in intracytoplasmic sperm injection.

Authors:  J Parinaud; P Milhet; G Vieitez; G Richoilley
Journal:  J Assist Reprod Genet       Date:  1999-01       Impact factor: 3.412

7.  Spontaneous development of anti-hepatitis B virus envelope (anti-idiotypic) antibodies in animals immunized with human liver endonexin II or with the F(ab')2 fragment of anti-human liver endonexin II immunoglobulin G: evidence for a receptor-ligand-like relationship between small hepatitis B surface antigen and endonexin II.

Authors:  K Hertogs; E Depla; T Crabbé; W De Bruin; W Leenders; H Moshage; S H Yap
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

Review 8.  Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.

Authors:  P C Rensen; R L de Vrueh; T J van Berkel
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

9.  Novel role for albumin in innate immunity: serum albumin inhibits the growth of Blastomyces dermatitidis yeast form in vitro.

Authors:  Steven Giles; Charles Czuprynski
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  Structure and glycosylation patterns of surface proteins from woodchuck hepatitis virus.

Authors:  T K Tolle; D Glebe; M Linder; D Linder; S Schmitt; R Geyer; W H Gerlich
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.